Palisade Bio Announces Executive Leadership Transition
October 11, 2022 09:25 ET
|
Palisade Bio, Inc.
Board Appoints JD Finley to Interim Chief Executive Officer Carlsbad, CA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company...
Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 23, 2022 16:30 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...